Investor's Business Daily on MSN
Why psychedelics-tied Compass Pathways reversed its premarket losses
Compass Pathways stock reversed higher Tuesday on positive test results for its psychedelic drug in treatment-resistant depression.
6hon MSN
Compass Pathways highlights long-term data from resistant depression, backs 2027 launch timeline
Compass Pathways plc CMPS on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the ...
Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed. The study ...
Per the consensus of Wall Street analysts, Compass Pathways (NASDAQ: CMPS) stock is on track for an absolutely stellar 12 months. They see its shares rising by 307% compared to where it is today. For ...
Good day, ladies and gentlemen, and welcome to COMPASS Pathways' Second Quarter 2024 Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce ...
CRISPR Therapeutics, co-developer of the CASGEVY gene-editing cure for sickle cell disease and beta-thalassemia, was added to ...
Is CMPS a good stock to buy? We came across a bullish thesis on COMPASS Pathways plc on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on CMPS. COMPASS Pathways plc's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results